Rigel Pharmaceuticals is transitioning from its immune thrombocytopenia (ITP) roots to become a multi-product oncology company. Its new drug VEPPANU is launching in the U.S. to address a $1 billion market for ESR1-mutated breast cancer, although early sales are not yet reflected in current forecasts. Rigel’s stock trades at a discount compared to sector averages despite strong sales growth and high profit margins in its base business. Investors will be watching upcoming Q3 results for updates on key products like TAVALISSE, GAVRETO, REZLIDHIA, and the initial market uptake of VEPPANU.
Regarding Rigel Pharmaceuticals, here is Pluang's health sector market snapshot as of Oct 22, 2026 18:01 WIB: Out of 150 priced US health stocks, 68 rose and 75 fell today. Notable movers include CRSP at USD 49.34 with a 1-day change of -2.30% and 100% buy order activity, HIMS at USD 28.71 down 1.71% with 100% buy order activity, and MRNA at USD 241.61 down 1.71% with 57% sell order activity. The most notable figure is CRSP's typical hold time on Pluang of 78 days.
Lockheed Martin reported strong Q3 2026 results, beating Wall Street estimates with earnings of $7.97 per share and sales of $20.7 billion, up 11% year-over-year. Net earnings rose 14% to $1.8 billion, supported by a record backlog of $292 billion, i...
IBM reported strong Q3 results with revenue of $17.1 billion and adjusted earnings of $2.95 per share, surpassing analyst estimates. Software revenue grew 9%, led by Red Hat and OpenShift, while AI-related consulting work also contributed significant...
Cowen & Co. initiated a 'Buy' rating on CenterPoint Energy before its Q3 earnings report due October 27, 2026. Analysts expect $2.16 billion in revenue, an 8.4% increase year-over-year, and earnings of $0.50 per share, steady from last year. The comp...
Drofa Comms has released the Women Leading the Way Digital Magazine 2026, aiming to highlight women experts in finance on equal terms with men. The digital magazine features insights from 25 industry professionals and covers topics like AI in wealth ...
Tesla reported third-quarter earnings with free cash flow exceeding expectations, but shares fell after hours despite an initial gain. The company lowered its full-year capital expenditure forecast to about $20 billion from over $25 billion, signalin...
